The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS). View on euronews

Eli Lilly will raise the UK list price of its weight-loss and type 2 diabetes treatment Mounjaro by up to 170% to be in line with other European markets, it said on Thursday, as the pharma industry responds to U.

Eli Lilly ( NYSE: LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 diabetes, by up to 170% in the UK starting in September. The move comes as President Donald Trump has put pressure on pharma companies to align US drug prices to what they are in other parts of the world.